Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ozen Leylek
Observed names:
Leylek, Özen,
O.A. Leylek
Institutions:
Queen Mary University of London,
Koch Institute for Integrative Cancer Research At MIT,
Barts Cancer Institute,
Massachusetts Institute of Technology
Observed institutions:
Koç University,
Queen Mary University of London,
Koch Institute for Integrative Cancer Research At MIT,
Barts Cancer Institute,
Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi,
Massachusetts Institute of Technology
show all 6
ORCID:
0000-0001-5772-725X
Observed ORCID:
0000-0001-5772-725X
OpenAlex ID:
A5037070802
Phenotypic heterogeneity and plasticity in colorectal cancer metastasis
2025
·
Samuel Ogden
, Nasrine Metic
, et al.
·
Cell Genomics
·
42
Resorufin Enters the Photodynamic Therapy Arena: A Monoamine Oxidase Activatable Agent for Selective Cytotoxicity
2020
·
Toghrul Almammadov
, Gizem Atakan
, et al.
·
ACS Medicinal Chemistry Letters
·
27
Leveraging platinum-protein interactions to overcome chemoresistance
2025
·
Fang Wang
, Jonathan Braverman
, et al.
·
Nature Communications
·
8
PDF
Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy
2024
·
Ozen Leylek
, Megan E. Honeywell
, et al.
·
Gastric Cancer
·
6
Abstract P023: Achieving synergism in combination chemotherapy for gastric cancer treatment
2021
·
Ozen Leylek
, Gulnihal Ozcan
·
Molecular Cancer Therapeutics
The variations of AMH serum concentrations after COH treatment
2014
·
O.A. Leylek
, B. Tiras
, et al.
·
Fertility and Sterility
Show more works
View as search
Works count:
7
Citation count:
83
H-index:
4
I10-index:
2
Year
Topic
Type